Influenza, Myocardial infarction, Pneumonia
Conditions
Brief summary
Incidence of an acute coronary syndrome (ACS) up to day 180
Detailed description
Incidence of 4-point MACE (nonfatal stroke, nonfatal myocardial infarction, cardiovascular death and coronary revascularization) up to day 180, Incidence of major bleeding complication and clinically relevant non-major bleeding up to day 90, Length of hospital stay, Mortality at day 90 and day 180, Societal costs up to day 180 measured with IMCQ and IPCQ, Health-related quality of life measured with the EQ-5D-5L
Interventions
DRUGPantoprazol Teva 20 mg maagsapresistente tabletten
DRUGPLACEBO
Sponsors
Amsterdam UMC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of an acute coronary syndrome (ACS) up to day 180 | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of 4-point MACE (nonfatal stroke, nonfatal myocardial infarction, cardiovascular death and coronary revascularization) up to day 180, Incidence of major bleeding complication and clinically relevant non-major bleeding up to day 90, Length of hospital stay, Mortality at day 90 and day 180, Societal costs up to day 180 measured with IMCQ and IPCQ, Health-related quality of life measured with the EQ-5D-5L | — |
Countries
Netherlands
Outcome results
None listed